Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of Moderate Buy from Brokerages

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target […]

Related Keywords

Canada ,United States ,America ,Michael Crowley ,Bio Rad Laboratories Inc ,Principal Securities Inc ,Bio Rad Laboratories Company Profile ,Citigroup ,Royal Bank ,Income Strategies ,Securities Exchange Commission ,Bio Rad Laboratories ,Get Free Report ,Marketbeat Ratings ,Exchange Commission ,Capital Management ,Rad Laboratories ,Get Free ,Life Science ,Bio Rad Laboratories Daily ,Nyse Bio ,Bio ,Medical ,09057220 ,Ratings ,Consensus ,